AMF Tjanstepension AB grew its holdings in Xylem Inc. (NYSE:XYL - Free Report) by 5.8% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 881,446 shares of the industrial products company's stock after buying an additional 48,329 shares during the quarter. Xylem makes up 0.8% of AMF Tjanstepension AB's portfolio, making the stock its 29th largest position. AMF Tjanstepension AB owned 0.36% of Xylem worth $105,313,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. AlphaCore Capital LLC bought a new position in shares of Xylem in the 1st quarter valued at about $53,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of Xylem by 10.3% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 435,058 shares of the industrial products company's stock valued at $51,972,000 after purchasing an additional 40,563 shares during the last quarter. CenterBook Partners LP boosted its stake in shares of Xylem by 20.5% in the 1st quarter. CenterBook Partners LP now owns 14,433 shares of the industrial products company's stock valued at $1,724,000 after purchasing an additional 2,459 shares during the last quarter. Headlands Technologies LLC boosted its stake in shares of Xylem by 90.6% in the 1st quarter. Headlands Technologies LLC now owns 305 shares of the industrial products company's stock valued at $36,000 after purchasing an additional 145 shares during the last quarter. Finally, Deutsche Bank AG boosted its stake in shares of Xylem by 6.8% in the 1st quarter. Deutsche Bank AG now owns 2,083,412 shares of the industrial products company's stock valued at $248,884,000 after purchasing an additional 131,897 shares during the last quarter. 87.96% of the stock is currently owned by institutional investors and hedge funds.
Xylem Stock Down 0.5%
Shares of XYL traded down $0.78 on Friday, hitting $142.71. The company's stock had a trading volume of 596,988 shares, compared to its average volume of 1,140,855. The company has a quick ratio of 1.43, a current ratio of 1.90 and a debt-to-equity ratio of 0.17. The firm's fifty day moving average price is $131.23 and its 200-day moving average price is $125.14. Xylem Inc. has a fifty-two week low of $100.47 and a fifty-two week high of $145.33. The firm has a market capitalization of $34.74 billion, a price-to-earnings ratio of 37.07, a P/E/G ratio of 2.48 and a beta of 1.11.
Xylem (NYSE:XYL - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The industrial products company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.15 by $0.11. Xylem had a return on equity of 10.33% and a net margin of 10.74%. The business had revenue of $2.30 billion during the quarter, compared to analyst estimates of $2.20 billion. During the same period in the previous year, the firm earned $1.09 EPS. Xylem's quarterly revenue was up 6.1% compared to the same quarter last year. On average, equities research analysts expect that Xylem Inc. will post 4.65 EPS for the current year.
Xylem Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 26th. Investors of record on Thursday, May 29th were given a $0.40 dividend. The ex-dividend date was Thursday, May 29th. This represents a $1.60 annualized dividend and a dividend yield of 1.1%. Xylem's payout ratio is currently 41.56%.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on XYL shares. Royal Bank Of Canada raised their target price on shares of Xylem from $143.00 to $147.00 and gave the company an "outperform" rating in a research note on Wednesday, April 30th. Stifel Nicolaus boosted their target price on Xylem from $162.00 to $175.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Robert W. Baird decreased their target price on Xylem from $149.00 to $146.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. Wall Street Zen upgraded Xylem from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, Citigroup restated a "buy" rating and set a $152.00 target price (up from $137.00) on shares of Xylem in a research report on Monday, July 14th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $151.57.
Check Out Our Latest Report on XYL
Xylem Company Profile
(
Free Report)
Xylem Inc, together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions worldwide. It operates through four segments: Water Infrastructure, Applied Water, Measurement & Control Solutions, and Integrated Solutions and Services. The Water Infrastructure segment offers products, including water, storm water, and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment and rental services under the ADI, Flygt, Godwin, Sanitaire, Magneto, Neptune Benson, Ionpure, Leopold, Wedeco, and Xylem Vue brands.
Recommended Stories

Before you consider Xylem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xylem wasn't on the list.
While Xylem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.